Notably, STEAP1 is often co-expressed with PSMA on prostate cancer cells, suggesting its utility in patients with heterogeneous PSMA expression or as part of multi-antigen targeting approaches [9,40]. This evidence concerns the gene FOLH1 and prostate carcinoma.